These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34176250)

  • 21. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.
    Jin Z; Cao Y; Lu Z; Liu C; Shen L
    Int Immunopharmacol; 2024 Aug; 137():112364. PubMed ID: 38865752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
    Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
    Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
    Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
    Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and Safety of PD-1 Blockades Among Elderly Patients with Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Study.
    Bai M; Wang WX; Deng T; Duan JJ; Ba Y
    Drug Des Devel Ther; 2024; 18():4135-4151. PubMed ID: 39308693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma.
    Ogura N; Yamamoto S; Kato K
    Expert Opin Biol Ther; 2024 Jun; 24(6):503-509. PubMed ID: 38860728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
    Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites.
    Guo JC; Lin CY; Lin CC; Huang TC; Lien MY; Lu LC; Kuo HY; Hsu CH
    Oncology; 2021; 99(10):652-658. PubMed ID: 34340231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
    Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
    Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
    Abraham P; Gricar J; Zhang Y; Shankaran V
    Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma.
    Wei T; Ti W; Song Q; Cheng Y
    Curr Oncol; 2022 Apr; 29(5):2920-2927. PubMed ID: 35621628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
    JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
    Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
    Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
    Gao TT; Shan JH; Yang YX; Zhang ZW; Liu SL; Xi M; Liu MZ; Zhao L
    BMC Cancer; 2022 Sep; 22(1):992. PubMed ID: 36115960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.
    Yang G; Sun H; Zhou C; Sun N; Xu L; Huang W; Li B
    J Cancer Res Ther; 2022 Apr; 18(2):545-552. PubMed ID: 35645126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
    Zhu X; Shanzhou Q; Li D; Pang X; Ma D
    BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
    Danese M; Gricar J; Abraham P
    Future Oncol; 2022 Mar; 18(8):927-936. PubMed ID: 35081734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
    Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
    Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
    Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
    N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients.
    Li H; Li B; Wang X; Zhang H; Wang C; Fan B; Wang L
    Nutrition; 2024 Aug; 124():112462. PubMed ID: 38663128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.